Improving inhalation delivery of a new treatment for cystic fibrosis
Optimizing ELD607 for Delivery by Inhalation
This study is testing a new inhaled treatment called ELD607 for people with cystic fibrosis to help reduce lung inflammation and improve their breathing by targeting a specific protein involved in their condition.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Kansas Medical Center NIH-funded |
| Lab location | 1 site (Kansas City, United States) |
| Project ID | NIH-11306886 on NIH RePORTER |
What this research studies
This research focuses on optimizing a novel treatment called ELD607, which targets a specific protein involved in inflammation in cystic fibrosis (CF) patients. The study aims to enhance the delivery of this treatment through inhalation, making it more effective for patients suffering from chronic lung infections and inflammation. By inhibiting the Orai1 protein, the research seeks to reduce neutrophilic inflammation and prevent further lung damage in CF patients. The approach involves both laboratory and clinical methodologies to ensure the treatment is safe and effective for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with cystic fibrosis, especially those experiencing chronic lung infections and inflammation.
Not a fit: Patients without cystic fibrosis or those whose condition is not related to neutrophilic inflammation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for cystic fibrosis patients, particularly those with severe lung inflammation.
How similar studies have performed: While the approach of targeting Orai1 for inflammation in cystic fibrosis is novel, similar strategies targeting inflammation in other diseases have shown promise.
Where this research is happening
Kansas City, United States
- University of Kansas Medical Center — Kansas City, United States (Active)
Researchers
- Principal investigator: Tarran, Robert — University of Kansas Medical Center
- Study coordinator: Tarran, Robert
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.